Skip to main content

Table 4 Adjusted screening performance measurements with 95% confidence intervals using GEE to account for correlations between mammograms of the same woman and to correct for the confounders percent dense volume and breast volume

From: Influence of breast compression pressure on the performance of population-based mammography screening

  Group 1 Group 2 Group 3 Group 4 Group 5
Recall/1000 26.1
(24.0–28.5)
20.8
(19.1–22.6)
22.0
(20.3–23.9)
21.0
(19.3–22.8)
22.2
(20.3–24.3)
False positives/1000 20.0
(18.1–22.1)
14.8
(13.4–16.4)
15.1
(13.7–16.6)
15.2
(13.8–16.8)
16.2
(14.6–18.0)
Screen-detected cancers/1000 6.1
(5.2–7.2)
5.9
(5.0–6.9)
6.9
(6.0–8.0)
5.7
(4.9–6.7)
5.9
(4.9–7.0)
Interval cancers/1000 1.3
(0.9–1.8)
1.6
(1.2–2.2)
1.6
(1.2–2.1)
2.2
(1.7–2.8)
2.3
(1.7–3.0)
Program sensitivity (%)* 82.0
(75.6–87.0)
77.1
(70.9–82.4)
79.8
(74.2–84.4)
71.1
(64.5–79.8)
70.8
(63.6–77.1)
12 month sensitivity (%)** 90.1
(84.4–93.9)
92.0
(87.2–95.1)
93.9a
(89.7–96.5)
87.2
(81.3–91.4)
84.3a
(77.3–89.4)
Specificity (%) 98.0a,b,c
(97.8–98.2)
98.5a
(98.3–98.7)
98.5b
(98.3–98.6)
98.5c
(98.3–98.6)
98.4
(98.2–98.5)
Positive predictive value (%) 23.5
(20.2–27.3)
28.7
(25.0–32.7)
31.5
(27.9–35.3)
27.3
(23.7–31.1)
26.7
(22.9–30.8)
  1. Pair-wise testing was applied on the sensitivity and specificity measurements and each subscript letter denotes a pair of pressure categories whose measurements differ significantly from each other
  2. The Tukey method was used for correction for multiple testing and a p value below 0.05 was considered significant
  3. The programm sensitivity (*) is calculated with all interval cancers, the 12-month sensitivity (**) is calculated with the interval cancers that were detected within 12 months after the examination